SunWay Biotech Co., LTD. (TPEX:1271)
Taiwan · Delayed Price · Currency is TWD 59.90
-1.00 (-1.64%)
Aug 19, 2026, 9:35 AM CST
SunWay Biotech Co., LTD. Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 1,535 | 993.3 | 970.18 | 571.11 | 425.35 | 380.43 | |
Revenue Growth | 61.34% | 2.38% | 69.88% | 34.27% | 11.81% | 20.97% |
Cost of Revenue | 815.49 | 432.8 | 425.14 | 334.45 | 275.46 | 109.32 |
Gross Profit | 719.69 | 560.5 | 545.04 | 236.67 | 149.89 | 271.11 |
Selling, General & Admin | 582.92 | 412.84 | 350.04 | 177.4 | 111.03 | 60 |
Research & Development | 39.91 | 43.53 | 54.02 | 6.21 | - | 43.38 |
Operating Expenses | 623.54 | 456.37 | 404.06 | 184.57 | 110.66 | 103.82 |
Operating Income | 96.16 | 104.13 | 140.98 | 52.1 | 39.23 | 167.29 |
Interest Expense | -26.6 | -11.26 | -5.54 | -2.09 | -1.15 | -0.09 |
Interest & Investment Income | 3.42 | 3.42 | 2.99 | 1.79 | 0.23 | 0.06 |
Earnings From Equity Investments | 46 | 20.32 | -0.04 | - | - | - |
Currency Exchange Gain (Loss) | -1.71 | -1.71 | 2.62 | 3.29 | 1.7 | -0.12 |
Other Non Operating Income (Expenses) | 34.29 | 0.32 | 1.02 | 1.14 | -0.38 | 3.21 |
EBT Excluding Unusual Items | 151.55 | 115.22 | 142.02 | 56.23 | 39.63 | 170.35 |
Gain (Loss) on Sale of Assets | 0.2 | 0.2 | - | - | - | - |
Asset Writedown | - | - | - | - | - | -0.14 |
Other Unusual Items | - | - | 0.07 | -0.31 | - | - |
Pretax Income | 151.75 | 115.42 | 142.09 | 55.92 | 39.63 | 170.21 |
Income Tax Expense | 15.07 | 13.93 | 23.53 | 9.79 | 8.29 | 0.49 |
Earnings From Continuing Operations | 136.69 | 101.49 | 118.56 | 46.13 | 31.34 | 169.72 |
Minority Interest in Earnings | 0.03 | 0.01 | 0.01 | -0.04 | -1.3 | -0.96 |
Net Income | 136.71 | 101.5 | 118.57 | 46.09 | 30.04 | 168.76 |
Net Income to Common | 136.71 | 101.5 | 118.57 | 46.09 | 30.04 | 168.76 |
Net Income Growth | 61.10% | -14.39% | 157.26% | 53.42% | -82.20% | 34.24% |
Shares Outstanding (Basic) | 62 | 60 | 60 | 31 | 20 | 34 |
Shares Outstanding (Diluted) | 62 | 60 | 60 | 31 | 20 | 34 |
Shares Change | 2.75% | -0.22% | 97.22% | 51.54% | -41.13% | 5.76% |
EPS (Basic) | 2.20 | 1.68 | 1.96 | 1.51 | 1.49 | 5.01 |
EPS (Diluted) | 2.20 | 1.68 | 1.96 | 1.50 | 1.48 | 4.92 |
EPS Growth | 57.05% | -14.29% | 30.26% | 1.33% | -69.80% | 26.90% |
Free Cash Flow | -38 | 121.25 | 40.73 | 9.75 | 42.58 | 151.05 |
Free Cash Flow Per Share | -0.61 | 2.01 | 0.67 | 0.32 | 2.11 | 4.40 |
Dividend Per Share | 1.000 | 1.000 | 1.330 | 0.983 | 3.186 | 4.278 |
Dividend Growth | -24.81% | -24.81% | 35.24% | -69.14% | -25.52% | 55.36% |
Gross Margin | 46.88% | 56.43% | 56.18% | 41.44% | 35.24% | 71.26% |
Operating Margin | 6.26% | 10.48% | 14.53% | 9.12% | 9.22% | 43.97% |
Profit Margin | 8.91% | 10.22% | 12.22% | 8.07% | 7.06% | 44.36% |
Free Cash Flow Margin | -2.48% | 12.21% | 4.20% | 1.71% | 10.01% | 39.70% |
EBITDA | 153.54 | 152.89 | 188.21 | 63.78 | 44.22 | 177.12 |
EBITDA Margin | 10.00% | 15.39% | 19.40% | 11.17% | 10.40% | 46.56% |
D&A For EBITDA | 57.38 | 48.76 | 47.23 | 11.69 | 4.99 | 9.83 |
EBIT | 96.16 | 104.13 | 140.98 | 52.1 | 39.23 | 167.29 |
EBIT Margin | 6.26% | 10.48% | 14.53% | 9.12% | 9.22% | 43.97% |
Effective Tax Rate | 9.93% | 12.07% | 16.56% | 17.51% | 20.91% | 0.29% |